On May 21, 2013, Goldman Small Cap Research published an Article on Nuvilex, Inc. (OTCQB – NVLX). For your convenience, a copy of the article can be found below.
Nuvilex Leverages Disparate Expertise to Develop Cannabis-Focused Cancer Treatment
It is not often that a Company that has expertise in two distinct arenas can combine these two disparate groups to develop what could emerge as a unique and ground-breaking cancer treatment method. Interestingly, this may be the case with Nuvilex Inc. (OTCQB – NVLX), an international firm engaged in live-cell encapsulation technology to treat pancreatic cancer along with the development and study of the use of medical marijuana for the treatment of oncology patients.
Nuvilex (OTCQB – NVLX) joins a small number of firms that is studying the prospective medical efficacy of the components of marijuana that have shown medical activity known as “cannabinoids.” The Company is not reinventing the wheel in this venture but is instead smartly leveraging the expertise in its own Firm as part of its objective of shortening the time from product development to market.
For example, Nuvilex’s subsidiary, Medical Marijuana Sciences, Inc., was formed with the goal of building upon the Company’s many years of experience in developing “all-natural” products for various uses by studying the medical applications of cannabinoids and developing treatments for serious human diseases. This experience goes a long way in terms of the “man years” spent on natural product-based development by the Company, relative to many companies in the industry.
Importantly, the Company plans to meld its highly regarded live cell-encapsulation technology to treat certain cancers in clinical trials and other tests, with the use of cannabinoids which have demonstrated an ability to act anticancer agents in various studies. Clearly, this live-cell encapsulation technology and cannabinoid combination is both proprietary and unique relative to anything the market has seen to date.
Moreover, it is unlikely that any other Firm will emerge with a similar approach as it would take many years to develop a technology and system even close to the Nuvilex (OTCQB – NVLX) methodology. As a result, if early tests prove successful, this combination should provide Nuvilex (OTCQB – NVLX) with a leg up on other firms in both the traditional oncology and the medical marijuana development spaces.
GSCR was paid by a third party for this article.